Manufacturers’ views on outcome-based agreements
Introduction: utcome-based agreements (OBAs) are occasionally deployed to relieve the burden of high drug prices on healthcare budgets. However, it is not clear when manufacturers are willing to collaborate in establishing such agreements. Therefore, we explored the feasibility of OBAs from the manu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2021.1993593 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045527687692288 |
|---|---|
| author | Sahar Barjesteh van Waalwijk van Doorn-Khosrovani Lonneke Timmers Anke Pisters-van Roy Joël Gijzen Nicole M.A. Blijlevens Haiko Bloemendal |
| author_facet | Sahar Barjesteh van Waalwijk van Doorn-Khosrovani Lonneke Timmers Anke Pisters-van Roy Joël Gijzen Nicole M.A. Blijlevens Haiko Bloemendal |
| author_sort | Sahar Barjesteh van Waalwijk van Doorn-Khosrovani |
| collection | DOAJ |
| description | Introduction: utcome-based agreements (OBAs) are occasionally deployed to relieve the burden of high drug prices on healthcare budgets. However, it is not clear when manufacturers are willing to collaborate in establishing such agreements. Therefore, we explored the feasibility of OBAs from the manufacturer’s point of view. Methods: Dutch market-access experts from eight major pharmaceutical companies, globally active in the field of oncology, were interviewed. Opinions were compiled, and interviewees and their colleagues were then given the chance to review the manuscript for additional comments. Results: Most interviewees believe that OBAs can be useful in providing access to off-label use of authorised medicines, especially when no alternative treatment is available for seriously ill patients. For the licenced indications, manufacturers seem to be more inclined to collaborate when there is a potential incentive to improve market-access (e.g., if the product is not used because of concerns regarding its effectiveness). However, manufacturers are less likely to collaborate when there are greater financial risks for the company. Further concerns were definition of outcome or performance, the impact of compliance on the effectiveness of a drug, administrative burden, uncertainty regarding revenue recognition and the challenges of reimbursing combination therapies. Discussion: Market-access interviewees were generally positive about OBAs, however they were more reluctant towards OBAs for registered indications with low response-rate. The definition of performance or outcome and its clinical relevance and validity, the feasibility of OBAs and their administrative burden are relevant aspects that need to be addressed in advance. Ideally, countries should collaborate to share the outline of OBAs and create shared databases to accumulate evidence. |
| format | Article |
| id | doaj-art-2c82add5c86d4c679c4a8eb4cffafd74 |
| institution | DOAJ |
| issn | 2001-6689 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-2c82add5c86d4c679c4a8eb4cffafd742025-08-20T02:54:40ZengMDPI AGJournal of Market Access & Health Policy2001-66892021-01-019110.1080/20016689.2021.19935931993593Manufacturers’ views on outcome-based agreementsSahar Barjesteh van Waalwijk van Doorn-Khosrovani0Lonneke Timmers1Anke Pisters-van Roy2Joël Gijzen3Nicole M.A. Blijlevens4Haiko Bloemendal5CZ Health InsuranceNational Health Care Institute (Zorginstituut Nederland)CZ Health InsuranceCZ Health InsuranceRadboud University Medical CentreRadboud University Medical CentreIntroduction: utcome-based agreements (OBAs) are occasionally deployed to relieve the burden of high drug prices on healthcare budgets. However, it is not clear when manufacturers are willing to collaborate in establishing such agreements. Therefore, we explored the feasibility of OBAs from the manufacturer’s point of view. Methods: Dutch market-access experts from eight major pharmaceutical companies, globally active in the field of oncology, were interviewed. Opinions were compiled, and interviewees and their colleagues were then given the chance to review the manuscript for additional comments. Results: Most interviewees believe that OBAs can be useful in providing access to off-label use of authorised medicines, especially when no alternative treatment is available for seriously ill patients. For the licenced indications, manufacturers seem to be more inclined to collaborate when there is a potential incentive to improve market-access (e.g., if the product is not used because of concerns regarding its effectiveness). However, manufacturers are less likely to collaborate when there are greater financial risks for the company. Further concerns were definition of outcome or performance, the impact of compliance on the effectiveness of a drug, administrative burden, uncertainty regarding revenue recognition and the challenges of reimbursing combination therapies. Discussion: Market-access interviewees were generally positive about OBAs, however they were more reluctant towards OBAs for registered indications with low response-rate. The definition of performance or outcome and its clinical relevance and validity, the feasibility of OBAs and their administrative burden are relevant aspects that need to be addressed in advance. Ideally, countries should collaborate to share the outline of OBAs and create shared databases to accumulate evidence.http://dx.doi.org/10.1080/20016689.2021.1993593performance-based agreementsoutcome-based agreementsmarket-accessoncology drugsexpensive drugs |
| spellingShingle | Sahar Barjesteh van Waalwijk van Doorn-Khosrovani Lonneke Timmers Anke Pisters-van Roy Joël Gijzen Nicole M.A. Blijlevens Haiko Bloemendal Manufacturers’ views on outcome-based agreements Journal of Market Access & Health Policy performance-based agreements outcome-based agreements market-access oncology drugs expensive drugs |
| title | Manufacturers’ views on outcome-based agreements |
| title_full | Manufacturers’ views on outcome-based agreements |
| title_fullStr | Manufacturers’ views on outcome-based agreements |
| title_full_unstemmed | Manufacturers’ views on outcome-based agreements |
| title_short | Manufacturers’ views on outcome-based agreements |
| title_sort | manufacturers views on outcome based agreements |
| topic | performance-based agreements outcome-based agreements market-access oncology drugs expensive drugs |
| url | http://dx.doi.org/10.1080/20016689.2021.1993593 |
| work_keys_str_mv | AT saharbarjestehvanwaalwijkvandoornkhosrovani manufacturersviewsonoutcomebasedagreements AT lonneketimmers manufacturersviewsonoutcomebasedagreements AT ankepistersvanroy manufacturersviewsonoutcomebasedagreements AT joelgijzen manufacturersviewsonoutcomebasedagreements AT nicolemablijlevens manufacturersviewsonoutcomebasedagreements AT haikobloemendal manufacturersviewsonoutcomebasedagreements |